EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Other Sources: 9

Hesperidin

Also called: citrus flavanone

Hesperidin is a citrus flavanone that accounts for about 90% of the flavanone glycosides in orange juice and is concentrated in the solid parts and membranes of citrus fruits. Supplements provide hesperidin extracts or purified hesperidin.

Category
Other
Forms
Citrus hesperidin extracts or purified hesperidin; modified forms such as glucosyl hesperidin and micronized hesperidin
Strongest evidence
B Some positive trials
Reviewed
2026-10-30

Class 1 Well studied in people. A 2024 meta-analysis pooled 12 randomized controlled trials (589 participants) of hesperidin extracts or purified hesperidin (10 hesperidin, 1 2S-hesperidin, 1 glucosyl hesperidin) on cardiovascular risk factors; orange-juice trials were not included. [1]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied3 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Hesperidin does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Hesperidin, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Blood lipidsBA 2024 meta-analysis of 12 trials (589 participants) found lower LDL (-0.22 mmol/L) and total cholesterol (-0.20 mmol/L), with small changes in fasting glucose, QUICKI, ICAM-1, VCAM-1 and CRP; other risk factors showed no effect. [1]
Blood pressureCA 2019 meta-analysis of 10 RCTs (577 participants) found no effect on systolic (-0.85 mmHg) or diastolic (-0.48 mmHg) blood pressure, or on blood lipids. [2]
Blood glucose controlCA 2020 meta-analysis of 6 trials (318 participants) found no significant effect on fasting glucose, insulin, HbA1c, HOMA-IR or QUICKI. [3]
Inflammation and oxidative stress markersBA 2026 meta-analysis of 10 RCTs (532 participants) found lower C-reactive protein (SMD -0.43) and TNF-α (SMD -0.51), but no significant effect on IL-6 overall. [4]

Main constituents: Hesperidin (the flavonoid hesperetin with a rutinoside moiety attached) [5]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Trials in a 2024 meta-analysis gave 292 to 1,000 mg/day of hesperidin. [1]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    3 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • A 2024 meta-analysis reports no serious adverse effects in most trials; only 1 RCT recorded adverse effects (common cold symptoms, pain and conjunctivitis in 6 participants taking 500 mg/day glucosyl hesperidin). [1]
Quality

Identity, quality and standardization

  • Hesperidin has low solubility, which may affect its absorption and bioavailability. [1]
Regulation

Regulatory status

  • US: FDA had no questions about GRAS Notice 796 for orange extract (85% hesperidin) in foods and beverages such as flavored milk, yogurt, cereal bars, juices, tea and sports drinks at 500 mg per serving (closed February 20, 2019). [7]
  • US: FDA had no questions about GRAS Notice 901 for glucosyl hesperidin in beverages, tea and coffee, candy, milk products and juices at 500 mg per serving (closed November 9, 2020). [8]
  • US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [9]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Hesperidin, a flavanone glycoside (rutinoside) whose aglycone is hesperetin Flavonoids (flavanone glycoside) [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 3 entries naming hesperidin, each with diosmin or in a multi-ingredient combination (earliest NDI 78 submitted 2000-04-05; most recent NDI 513 submitted 2007-12-03). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P5]
  • FDA's GRAS Notice Inventory: FDA had no questions about GRN 796, orange extract (85% hesperidin), at 500 mg per serving in listed foods (closed February 20, 2019). [P3]
  • FDA's GRAS Notice Inventory: FDA had no questions about GRN 901, glucosyl hesperidin, at 500 mg per serving in listed foods (closed November 9, 2020). [P4]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of hesperidin was found (IARC Monographs list of classifications, Volumes 1–142, and NTP technical reports checked 2026-10-30). [P6]
  • The NTP Technical Reports index (TR-001 to TR-606) lists no study of hesperidin (checked 2026-10-30). [P7]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P8]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • Hesperidin's rutinoside moiety is proposed to limit its bioavailability; removing the rhamnose (to hesperetin-7-glucoside) moved absorption from the colon to the small intestine, with Tmax 0.6 ± 0.1 h. [P1]

Formulations studied to change absorption

Human data only.

  • In 16 healthy volunteers (randomized crossover), orange juice with enzyme-made hesperetin-7-glucoside gave a plasma hesperetin AUC of 3.45 ± 1.27 versus 1.16 ± 0.52 for natural hesperidin juice, and about 4-fold higher Cmax (AUC units as printed in the abstract: mmol/(L·h)). [P1]
  • In 15 healthy individuals given 500 mg, relative urinary excretion was 70 ± 14% for micronized 2S-hesperidin, 55 ± 15% for a micronized 2S/2R mixture and 43 ± 8.0% for the non-micronized mixture. [P2]

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Nielsen IL, et al. Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. J Nutr 2006;136(2):404-408 (PMID 16424119), 2006-02. pubmed.ncbi.nlm.nih.gov
  2. Crescenti A, et al. Hesperidin Bioavailability Is Increased by the Presence of 2S-Diastereoisomer and Micronization: A Randomized, Crossover and Double-Blind Clinical Trial. Nutrients 2022;14(12):2481 (PMID 35745211), 2022-06-15. pubmed.ncbi.nlm.nih.gov
  3. U.S. FDA. GRAS Notice Inventory: GRN No. 796, Orange extract (85% hesperidin), 2019-02-20. hfpappexternal.fda.gov
  4. U.S. FDA. GRAS Notice Inventory: GRN No. 901, Glucosyl hesperidin, 2020-11-09. hfpappexternal.fda.gov
  5. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  6. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142, 2026-10-30. monographs.iarc.who.int
  7. National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-30. ntp.niehs.nih.gov
  8. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
Sources

Sources

  1. Huang H, et al. Effects of Citrus Flavanone Hesperidin Extracts or Purified Hesperidin Consumption on Risk Factors for Cardiovascular Disease: Evidence From an Updated Meta-analysis of Randomized Controlled Trials. Curr Dev Nutr 2024;8(9):102055 (PMID 39279783; full text PMC11399677), 2023-12-09. pubmed.ncbi.nlm.nih.gov
  2. Mohammadi M, et al. Hesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials. Phytother Res 2019;33(3):534-545 (PMID 30632207), 2019-03. pubmed.ncbi.nlm.nih.gov
  3. Shams-Rad S, et al. Hesperidin supplementation has no effect on blood glucose control: a systematic review and meta-analysis of randomized controlled clinical trials. Br J Clin Pharmacol 2020;86(1):13-22 (PMID 31489695), 2019-12-12. pubmed.ncbi.nlm.nih.gov
  4. Ouyang L, et al. The effects of hesperidin supplementation on inflammation and oxidative stress in adults: a systematic review and meta-analysis. Br J Nutr 2026 (PMID 41883255), 2026-03-26. pubmed.ncbi.nlm.nih.gov
  5. Nielsen IL, et al. Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. J Nutr 2006;136(2):404-408 (PMID 16424119), 2006-02. pubmed.ncbi.nlm.nih.gov
  6. Crescenti A, et al. Hesperidin Bioavailability Is Increased by the Presence of 2S-Diastereoisomer and Micronization: A Randomized, Crossover and Double-Blind Clinical Trial. Nutrients 2022;14(12):2481 (PMID 35745211), 2022-06-15. pubmed.ncbi.nlm.nih.gov
  7. U.S. FDA. GRAS Notice Inventory: GRN No. 796, Orange extract (85% hesperidin), 2019-02-20. hfpappexternal.fda.gov
  8. U.S. FDA. GRAS Notice Inventory: GRN No. 901, Glucosyl hesperidin, 2020-11-09. hfpappexternal.fda.gov
  9. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.